This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy.
Participants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea/vomiting scores, sleep quality, quality of life, and cancer symptoms.
Pathologically and radio-graphically diagnosed lung cancer
Age greater than 18 years
Received platinum-based chemotherapy
Life expectancy of six months or longer
Inability to comply with timely supplementation administration.
Within 14 days prior to trial entry, laboratory data showing abnormal liver function, abnormal kidney function
Within 30 days prior to trial entry, unexplained fever ≥38.5°C for 7 consecutive days or chronic diarrhea for 15 consecutive days.
Currently receiving hormone therapy.
Tri-Service General Hospital
Lead sponsor
Balay Biotechnology Corporation
Collaborator